JPWO2019197842A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019197842A5 JPWO2019197842A5 JP2020555420A JP2020555420A JPWO2019197842A5 JP WO2019197842 A5 JPWO2019197842 A5 JP WO2019197842A5 JP 2020555420 A JP2020555420 A JP 2020555420A JP 2020555420 A JP2020555420 A JP 2020555420A JP WO2019197842 A5 JPWO2019197842 A5 JP WO2019197842A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- quinoline
- oxazepino
- chloro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DDNHKOMVKLDTQY-UHFFFAOYSA-N 7H-quinolin-6-one Chemical compound N1=CC=CC2=CC(CC=C12)=O DDNHKOMVKLDTQY-UHFFFAOYSA-N 0.000 claims 64
- 125000000217 alkyl group Chemical group 0.000 claims 51
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 47
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 239000001257 hydrogen Substances 0.000 claims 37
- -1 cyano, acetylenyl Chemical group 0.000 claims 35
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 18
- ZVBZUYIYZHXAFY-UHFFFAOYSA-N 1,7-dihydrooxazepino[6,5-c]quinoline-5,6-dione Chemical compound C1C=NOC(C=2C(NC=3C=CC=CC=3C=21)=O)=O ZVBZUYIYZHXAFY-UHFFFAOYSA-N 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000004438 haloalkoxy group Chemical group 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910005965 SO 2 Inorganic materials 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- SZCKSNPRMHFNIV-UHFFFAOYSA-N 2-ethyloctanamide Chemical compound CCCCCCC(CC)C(N)=O SZCKSNPRMHFNIV-UHFFFAOYSA-N 0.000 claims 2
- NDCQPJCNZBQYAO-UHFFFAOYSA-N 4-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 NDCQPJCNZBQYAO-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229940081066 picolinic acid Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- HGIIOSISILPQAD-QEEYODRMSA-N (2R)-10-[[5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl]pyrimidin-4-yl]amino]-2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-[1,4]thiazepino[2,3-c]quinolin-6-one Chemical compound ClC=1C(=NC(=NC=1)N1C[C@@H](C([C@@H](C1)C)(F)F)C)NC1=CC=2C3=C(C(N(C=2C=C1)C)=O)SCC[C@@H](N3)C1CC1 HGIIOSISILPQAD-QEEYODRMSA-N 0.000 claims 1
- LCMPNVYSMTYYJE-UHFFFAOYSA-N 2-chloro-4-[(2,7-dimethyl-5,6-dioxo-1,2,3,4-tetrahydro-[1,4]diazepino[6,5-c]quinolin-10-yl)amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC=2C3=C(C(N(C=2C=C1)C)=O)C(NCC(N3)C)=O LCMPNVYSMTYYJE-UHFFFAOYSA-N 0.000 claims 1
- CPRJDQUHIKJKEF-UHFFFAOYSA-N 2-chloro-4-[(2,7-dimethyl-6-oxospiro[2,4-dihydro-1H-[1,4]oxazepino[2,3-c]quinoline-3,1'-cyclopropane]-10-yl)amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC=2C3=C(C(N(C=2C=C1)C)=O)OCC1(C(N3)C)CC1 CPRJDQUHIKJKEF-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GCNQKCIUMOPHPN-UHFFFAOYSA-N O=C1C=C(C=CN=N2)C2=CC1 Chemical compound O=C1C=C(C=CN=N2)C2=CC1 GCNQKCIUMOPHPN-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000006193 alkinyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024082277A JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1806132.5 | 2018-04-13 | ||
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GB1819136.1 | 2018-11-23 | ||
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
| PCT/GB2019/051058 WO2019197842A1 (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024082277A Division JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021521165A JP2021521165A (ja) | 2021-08-26 |
| JP2021521165A5 JP2021521165A5 (https=) | 2022-02-07 |
| JPWO2019197842A5 true JPWO2019197842A5 (https=) | 2022-02-07 |
| JP7493454B2 JP7493454B2 (ja) | 2024-05-31 |
Family
ID=66240166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555420A Active JP7493454B2 (ja) | 2018-04-13 | 2019-04-12 | Ｂｃｌ６阻害剤 |
| JP2024082277A Pending JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024082277A Pending JP2024119835A (ja) | 2018-04-13 | 2024-05-21 | Ｂｃｌ６阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11512095B2 (https=) |
| EP (3) | EP4729127A2 (https=) |
| JP (2) | JP7493454B2 (https=) |
| KR (2) | KR102830237B1 (https=) |
| CN (2) | CN119330979A (https=) |
| AU (2) | AU2019253510B2 (https=) |
| BR (1) | BR112020020832A2 (https=) |
| CA (1) | CA3095371A1 (https=) |
| DK (1) | DK3774817T3 (https=) |
| ES (2) | ES3060268T3 (https=) |
| HR (1) | HRP20230120T1 (https=) |
| IL (2) | IL296734B2 (https=) |
| MX (2) | MX2020010805A (https=) |
| PT (1) | PT3774817T (https=) |
| SG (1) | SG11202009735QA (https=) |
| WO (1) | WO2019197842A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3060268T3 (en) | 2018-04-13 | 2026-03-25 | Cancer Research Tech Ltd | Bcl6 inhibitors |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CN115397821B (zh) * | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| MA69177B1 (fr) | 2022-06-06 | 2026-03-31 | Treeline Biosciences, Inc. | Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques |
| EP4536658A1 (en) | 2022-06-13 | 2025-04-16 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| EP4558487A1 (en) * | 2022-07-19 | 2025-05-28 | Dana-Farber Cancer Institute, Inc. | Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof |
| WO2024193464A1 (zh) * | 2023-03-17 | 2024-09-26 | 西藏海思科制药有限公司 | 一种含氮三并环衍生物及其在医药上的应用 |
| WO2025050016A1 (en) * | 2023-09-01 | 2025-03-06 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| WO2025049964A1 (en) * | 2023-09-01 | 2025-03-06 | Treeline Biosciences, Inc. | Bcl6 bifunctional degraders |
| CN120987969A (zh) * | 2024-05-21 | 2025-11-21 | 中国药科大学 | 一类蛋白靶向降解嵌合体及其用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0259572A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ベンズイミダゾロン誘導体又はその塩類 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP1144387A1 (en) | 1998-12-04 | 2001-10-17 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| WO2001005770A1 (en) | 1999-07-21 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| US8338464B2 (en) | 2006-11-30 | 2012-12-25 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of BCL6 |
| US8686008B2 (en) | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| ES2475206T3 (es) | 2008-02-01 | 2014-07-10 | Takeda Pharmaceutical Company Limited | Derivados de oxima como inhibidores de HSP90 |
| ES2443127T3 (es) * | 2008-11-11 | 2014-02-17 | Jeil Pharmaceutical Co., Ltd. | Nuevos derivados tricíclicos o sales de éstos farmacéuticamente aceptables, su procedimiento de fabricación y composiciones farmacéuticas que los contienen |
| PL2565193T3 (pl) | 2009-01-23 | 2014-07-31 | Rigel Pharmaceuticals Inc | Kompozycje i sposoby hamowania szlaku JAK |
| JP2013517273A (ja) | 2010-01-13 | 2013-05-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物および方法 |
| JP6116554B2 (ja) | 2011-07-07 | 2017-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | がんの処置のための置換されたアザ複素環 |
| MX357320B (es) | 2012-06-18 | 2018-07-04 | Dart Neuroscience Cayman Ltd | Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida. |
| BR112015021806A2 (pt) * | 2013-03-05 | 2017-07-18 | Hoffmann La Roche | inibidores de tirosina cinase de bruton |
| US9943506B2 (en) * | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| CN105017159B (zh) | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
| DK3185868T3 (da) | 2014-08-25 | 2022-05-23 | Salk Inst For Biological Studi | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme |
| WO2016033416A1 (en) | 2014-08-29 | 2016-03-03 | Board Of Regents, University Of Texas System | Bromodomain inhibitors for treating disease |
| CN107205993B (zh) | 2014-12-06 | 2021-03-09 | 细胞内治疗公司 | 有机化合物 |
| WO2017007658A1 (en) | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| JP6999688B2 (ja) * | 2016-12-13 | 2022-02-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体 |
| EP3630291B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| WO2018215798A1 (en) * | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| ES3060268T3 (en) | 2018-04-13 | 2026-03-25 | Cancer Research Tech Ltd | Bcl6 inhibitors |
| GB201819136D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
-
2019
- 2019-04-12 ES ES22211485T patent/ES3060268T3/es active Active
- 2019-04-12 EP EP25225215.0A patent/EP4729127A2/en active Pending
- 2019-04-12 KR KR1020207032149A patent/KR102830237B1/ko active Active
- 2019-04-12 CN CN202411445401.8A patent/CN119330979A/zh active Pending
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 IL IL296734A patent/IL296734B2/en unknown
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 EP EP22211485.2A patent/EP4201939B1/en active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 KR KR1020257022060A patent/KR20250105504A/ko active Pending
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en not_active Ceased
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt active Search and Examination
- 2019-04-12 CN CN201980039513.4A patent/CN112334475B/zh active Active
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US12486285B2/en active Active
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501B2/en active Active
-
2024
- 2024-05-21 JP JP2024082277A patent/JP2024119835A/ja active Pending
-
2025
- 2025-10-03 US US19/349,679 patent/US20260042776A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521165A5 (https=) | ||
| HRP20230120T1 (hr) | Inhibitori bcl6 | |
| EP4384177A1 (en) | Heterocyclic compounds and methods of use | |
| JP2024532735A (ja) | 複素環式化合物及び使用方法 | |
| AU2022265682A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| US20250163064A1 (en) | Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins | |
| JP2025533831A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質のテザー型複素環式阻害剤及びその使用 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| JP2015521600A5 (https=) | ||
| JPWO2020081848A5 (https=) | ||
| JP2019535664A5 (https=) | ||
| WO2024229317A1 (en) | Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| JPWO2019197842A5 (https=) | ||
| SI3083625T1 (en) | Pyrimidopyrimidinones, useful as Wee-1 kinase inhibitors | |
| IL318278A (en) | Imidazopyridazine and imidazopyridine compounds and their use | |
| JP2021527099A5 (https=) | ||
| JPWO2020207991A5 (https=) | ||
| WO2025217247A1 (en) | Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| WO2025194057A1 (en) | Macrocyclic compounds as modulators of kras and uses thereof | |
| WO2025230862A1 (en) | Macrocyclic amino compounds as modulators of kras and uses therof | |
| CN117897159A (zh) | 杂环化合物及使用方法 | |
| CN117835976A (zh) | 杂环化合物及使用方法 | |
| RU2023134860A (ru) | Ингибиторы мутации her2 | |
| RU2021131710A (ru) | Соединения гексагидро-1h-пиразино[1,2-a]пиразина для лечения аутоиммунного заболевания |